Zobrazeno 1 - 8
of 8
pro vyhledávání: '"J. J. J. van Giezen"'
Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
Autor:
Constance C. F. M. J. Baaten, Leo F. Veenstra, Rick Wetzels, Johanna P. van Geffen, Frauke Swieringa, Susanne M. de Witt, Yvonne M. C. Henskens, Harry Crijns, Sven Nylander, J. J. J. van Giezen, Johan W. M. Heemskerk, Paola E. J. van der Meijden
Publikováno v:
Haematologica, Vol 100, Iss 9 (2015)
In patients with acute coronary syndrome, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor like prasugrel is prescribed for one year. Here, we investigated how the hemostatic function of platelets recovers after discontinuation of prasugr
Externí odkaz:
https://doaj.org/article/ed2daf44169f4072994404a5a4b176e4
Autor:
Reyhan Nergiz-Unal, Judith M E M Cosemans, Marion A H Feijge, Paola E J van der Meijden, Robert F Storey, J J J van Giezen, Mirjam G A oude Egbrink, Johan W M Heemskerk, Marijke J E Kuijpers
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10130 (2010)
BACKGROUND: In most models of experimental thrombosis, healthy blood vessels are damaged. This results in the formation of a platelet thrombus that is stabilized by ADP signaling via P2Y(12) receptors. However, such models do not predict involvement
Externí odkaz:
https://doaj.org/article/bc768f16716b44a084e9400cf1ae2714
Autor:
J. J. J. Van Giezen, L. Nilsson, W. Tomlinson, B.-M. Wissing, Fabrizio Giordanetto, Pia Berntsson, P. J. Greasley
Publikováno v:
Journal of Thrombosis and Haemostasis. 7:1556-1565
Summary. Background: P2Y12 plays an important role in regulating platelet aggregation and function. This receptor is the primary target of thienopyridine antiplatelet agents, the active metabolites of which bind irreversibly to the receptor, and of n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0907540baec5c63ffbcd1768a2e0e619
https://doi.org/10.1111/j.1538-7836.2009.03527.x
https://doi.org/10.1111/j.1538-7836.2009.03527.x
Autor:
Li-Ming, Gan, Ann, Wittfeldt, Gunnar, Brandrup-Wognsen, J J J, van Giezen, Jenny, Jonasson, Sven, Nylander, Håkan, Emanuelsson
Publikováno v:
Journal of the American College of Cardiology. 62(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f929981dcd2a5c5fe83f826a77a6bec8
https://pubmed.ncbi.nlm.nih.gov/23747764
https://pubmed.ncbi.nlm.nih.gov/23747764
Autor:
Peter, Bach, Jonas, Boström, Kay, Brickmann, J J J, van Giezen, Robert D, Groneberg, Darren M, Harvey, Michael, O'Sullivan, Fredrik, Zetterberg
Publikováno v:
European journal of medicinal chemistry. 65
The present paper describes the development of a new series of P2Y12 receptor antagonists based on our previously reported piperazinyl urea series 1 (IC50 binding affinity = 0.33 μM, aq solubility0.1 μM, microsomal CLint (HLM) ≥300 μM/min/mg). B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8fb19daa30b7cb2ccb198999edbc2305
https://pubmed.ncbi.nlm.nih.gov/23747805
https://pubmed.ncbi.nlm.nih.gov/23747805
Autor:
Marijke J E, Kuijpers, Remco T A, Megens, Elham, Nikookhesal, Marion A H, Feijge, J G R, De Mey, Mirjam G A, oude Egbrink, J J J, van Giezen, Johan W M, Heemskerk
Publikováno v:
Thrombosis and haemostasis. 106(6)
Platelet P2Y₁₂ receptors play an important role in arterial thrombosis by stimulating thrombus growth. Both irreversibly (clopidogrel) and reversibly binding (ticagrelor, AZD6140) P2Y₁₂ antagonists are clinically used for restricted periods,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2686ef2aae16451c4e041b965b6552e2
https://pubmed.ncbi.nlm.nih.gov/22071958
https://pubmed.ncbi.nlm.nih.gov/22071958
Autor:
S, Husted, J J J, van Giezen
Publikováno v:
International journal of clinical practice. 61(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6f317f35ef2bc632d0d4291175ea2128
https://pubmed.ncbi.nlm.nih.gov/17313629
https://pubmed.ncbi.nlm.nih.gov/17313629
Publikováno v:
Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 9(1)
We studied the effects of PRAP-1, a PAI-1-inhibiting polyclonal antibody, on tissue-type plasminogen activator (t-PA)-induced lysis of arterial-like thrombi prepared in vitro from rat and human blood in a Chandler loop device. The t-PA induced lysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b5fdd70386ffbe31b76178554a58dd3
https://pubmed.ncbi.nlm.nih.gov/9607114
https://pubmed.ncbi.nlm.nih.gov/9607114